Objective: The objective of this study was to assess the predictive performance of preoperative cervical length (CL) for delivery within 1 week after pleuroamniotic shunting (PAS) in fetuses with severe hydrothorax. Methods: A prospective cohort of fetuses with severe hydrothorax referred to our fetal surgery center in Querétaro, Mexico from January 2012 to July 2020. Severe fetal hydrothorax was diagnosed as an accumulation of fluid within the fetal pleural space accompanied with severe bilateral lung compression, mediastinal shift, polyhydramnios, and/or hydrops. Transvaginal CL was measured immediately before PAS, and a short cervix was defined as that <25 mm. The interval from fetal intervention to delivery, prevalence of preterm prelabor rupture of membranes (PPROMs), and associations with delivery within the first week after PAS according to a short or a normal CL, were evaluated. Results: Thirty-five pregnancies with severe fetal hydrothorax treated with PAS were evaluated. Median gestational age at PAS was (weeks + days) 31+2 (range, 26+0–36+1). Two (5.7%) and 7 (20.0%) cases delivered within the first 24 h and 1 week after PAS, respectively. Ten (28.6%) women had a short cervix before PAS, while 25 (71.4%) had normal preoperative CL. Women with a short cervix showed lower mean interval between fetal intervention and delivery (2.4 vs. 5.5 weeks, p = 0.01), and higher prevalence of PPROM (50 vs. 12%, p = 0.01), as compared to women with a nonshort cervix. Preoperative short cervix was associated with significantly higher risk of delivery within the first 24 h (20.0 vs. 0%, respectively, p < 0.05) and 1 week after PAS (50.0 vs. 8.0%, respectively, p < 0.01) compared with pregnancies with normal preoperative CL. Conclusion: In pregnancies with severe fetal hydrothorax candidates for pleuroamniotic shunt, identification of a short cervix before fetal intervention can predict delivery within 1 week after the surgical procedure.

1.
Longaker
MT
,
Laberge
JM
,
Dansereau
J
,
Langer
JC
,
Crombleholme
TM
,
Callen
PW
, et al
Primary fetal hydrothorax: natural history and management
.
J Pediatr Surg
.
1989 Jun
;
24
(
6
):
573
6
. .
2.
Attar
MA
,
Donn
SM
.
Congenital chylothorax
.
Semin Fetal Neonatal Med
.
2017 Aug
;
22
(
4
):
234
9
. .
3.
Ruano
R
,
Ramalho
AS
,
Cardoso
AK
,
Moise
K
 Jr
,
Zugaib
M
.
Prenatal diagnosis and natural history of fetuses presenting with pleural effusion
.
Prenat Diagn
.
2011 May
;
31
(
5
):
496
9
. .
4.
Deurloo
KL
,
Devlieger
R
,
Lopriore
E
,
Klumper
FJ
,
Oepkes
D
.
Isolated fetal hydrothorax with hydrops: a systematic review of prenatal treatment options
.
Prenat Diagn
.
2007 Oct
;
27
(
10
):
893
9
. .
5.
Yinon
Y
,
Grisaru-Granovsky
S
,
Chaddha
V
,
Windrim
R
,
Seaward
PG
,
Kelly
EN
, et al
Perinatal outcome following fetal chest shunt insertion for pleural effusion
.
Ultrasound Obstet Gynecol
.
2010 Jul
;
36
(
1
):
58
64
. .
6.
Pellegrinelli
JM
,
Kohler
A
,
Kohler
M
,
Weingertner
AS
,
Favre
R
.
Prenatal management and thoracoamniotic shunting in primary fetal pleural effusions: a single centre experience
.
Prenat Diagn
.
2012 May
;
32
(
5
):
467
71
. .
7.
Wada
S
,
Jwa
SC
,
Yumoto
Y
,
Takahashi
Y
,
Ishii
K
,
Usui
N
, et al
The prognostic factors and outcomes of primary fetal hydrothorax with the effects of fetal intervention
.
Prenat Diagn
.
2017 Feb
;
37
(
2
):
184
92
. .
8.
Dorsi
M
,
Giuseppi
A
,
Lesage
F
,
Stirnemann
J
,
De Saint Blanquat
L
,
Nicloux
M
, et al
Prenatal factors associated with neonatal survival of infants with congenital chylothorax
.
J Perinatol
.
2018 Jan
;
38
(
1
):
31
4
. .
9.
Iams
JD
,
Goldenberg
RL
,
Meis
PJ
,
Mercer
BM
,
Moawad
A
,
Das
A
, et al
The length of the cervix and the risk of spontaneous premature delivery. National institute of child health and human development maternal fetal medicine unit network
.
N Engl J Med
.
1996 Feb 29
;
334
(
9
):
567
72
. .
10.
Society for Maternal-Fetal
M
,
Norton
ME
,
Chauhan
SP
,
Dashe
JS
.
Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis
.
Am J Obstet Gynecol
.
2015 Feb
;
212
(
2
):
127
39
. .
11.
Society for Maternal-Fetal Medicine. Electronic address pso
;
Dashe
JS
,
Dashe
JS
,
Pressman
EK
,
Hibbard
JU
.
SMFM consult series #46: evaluation and management of polyhydramnios
.
Am J Obstet Gynecol
.
2018 Oct
;
219
(
4
):
B2
8
. .
12.
Burger
M
,
Weber-Rössler
T
,
Willmann
M
.
Measurement of the pregnant cervix by transvaginal sonography: an interobserver study and new standards to improve the interobserver variability
.
Ultrasound Obstet Gynecol
.
1997 Mar
;
9
(
3
):
188
93
. .
13.
Rodeck
CH
,
Fisk
NM
,
Fraser
DI
,
Nicolini
U
.
Long-term in utero drainage of fetal hydrothorax
.
N Engl J Med
.
1988 Oct 27
;
319
(
17
):
1135
8
. .
14.
Berger
VK
,
Sparks
TN
,
Jelin
AC
,
Derderian
C
,
Jeanty
C
,
Gosnell
K
, et al
Non-immune hydrops fetalis: do placentomegaly and polyhydramnios matter?
J Ultrasound Med
.
2018 May
;
37
(
5
):
1185
91
. .
15.
Engineer
N
,
O'Donoghue
K
,
Wimalasundera
RC
,
Fisk
NM
.
The effect of polyhydramnios on cervical length in twins: a controlled intervention study in complicated monochorionic pregnancies
.
PLoS One
.
2008
;
3
(
12
):
e3834
. .
16.
Hershkovitz
R
,
Sheiner
E
,
Maymon
E
,
Erez
O
,
Mazor
M
.
Cervical length assessment in women with idiopathic polyhydramnios
.
Ultrasound Obstet Gynecol
.
2006 Nov
;
28
(
6
):
775
8
. .
17.
Takahashi
Y
,
Kawabata
I
,
Sumie
M
,
Nakata
M
,
Ishii
K
,
Murakoshi
T
, et al
Thoracoamniotic shunting for fetal pleural effusions using a double-basket shunt
.
Prenat Diagn
.
2012 Dec
;
32
(
13
):
1282
7
. .
18.
Miyoshi
T
,
Katsuragi
S
,
Ikeda
T
,
Horiuchi
C
,
Kawasaki
K
,
Kamiya
CA
, et al
Retrospective review of thoracoamniotic shunting using a double-basket catheter for fetal chylothorax
.
Fetal Diagn Ther
.
2013
;
34
(
1
):
19
25
. .
19.
Cobo
T
,
Palacio
M
,
Eixarch
E
,
Crispi
F
,
Mercadé
I
,
Martínez-Crespo
JM
, et al
Clinical and biochemical predictors of very preterm birth in twin-to-twin transfusion syndrome treated by fetoscopy
.
Am J Obstet Gynecol
.
2011 Jan
;
204
(
1
):
58.e1
5
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.